← Leaderboards
Verline Justilien
Mayo Clinic Jacksonville
$1,657,267
Attributed
$2,536,142
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $503.8K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,536,142 · 4
By mechanism
R01$1,757,751 · 1
R21$621,891 · 2
R03$156,500 · 1
Top collaborators
- Alan P Fields6 shared
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesTumor GrowthCellsIn VivoTumorOncogenicEventMalignant Neoplasm Of LungOverexpressionGenetic TranscriptionUnited StatesGeneticCancer EtiologyGrowthCessation Of LifeNeoplastic CellPhenotypeLung AdenocarcinomaTp53 GeneTumor InitiationPremalignantDiagnosisDesignProteins
Grant awards (11)
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma$284,301
R01 · FY2025 · CA
ECT2 Isoform Switch in Pancreatic Cancer.$219,491
R21 · FY2025 · CA · contact PI
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma$340,095
R01 · FY2024 · CA
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma$350,834
R01 · FY2023 · CA
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma$350,834
R01 · FY2022 · CA
Investigating cells of origin and oncogenic modifiers of 3q26-driven LUSC$73,693
R01 · FY2022 · CA
A Genetically Tractable Mouse Model for PRKCI-driven Lung Squamous Cell Carcinoma$357,994
R01 · FY2021 · CA
3q26 Amplified Genes as Cooperative Oncogenic Drivers of Lung Squamous Cell Carcinoma$78,250
R03 · FY2020 · CA · contact PI
3q26 Amplified Genes as Cooperative Oncogenic Drivers of Lung Squamous Cell Carcinoma$78,250
R03 · FY2019 · CA · contact PI
Ect2 Function in Lung Adenocarcinoma Initiation and Maintenance$182,909
R21 · FY2017 · CA · contact PI
Ect2 Function in Lung Adenocarcinoma Initiation and Maintenance$219,491
R21 · FY2016 · CA · contact PI